Cargando…
Pseudophakic Cystoid Macular Oedema (PCME) Prevention in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)—Randomized Controlled Trial
Background and Objectives: The purpose of this study was to compare the effect of topical bromfenac and dexamethasone on the intraocular concentration of interleukin 6 (IL-6) and incidence of pseudophakic cystoid macular oedema (PCME) after cataract surgery in patients with non-proliferative diabeti...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694649/ https://www.ncbi.nlm.nih.gov/pubmed/36422204 http://dx.doi.org/10.3390/medicina58111667 |
_version_ | 1784837854399037440 |
---|---|
author | Jukić, Anđela Kasalica Žužul, Rajka Pavan, Josip Lovrić, Mila Kozmar, Ana Plavec, Davor Kuzman, Tomislav Kalauz, Miro Jukić, Tomislav |
author_facet | Jukić, Anđela Kasalica Žužul, Rajka Pavan, Josip Lovrić, Mila Kozmar, Ana Plavec, Davor Kuzman, Tomislav Kalauz, Miro Jukić, Tomislav |
author_sort | Jukić, Anđela |
collection | PubMed |
description | Background and Objectives: The purpose of this study was to compare the effect of topical bromfenac and dexamethasone on the intraocular concentration of interleukin 6 (IL-6) and incidence of pseudophakic cystoid macular oedema (PCME) after cataract surgery in patients with non-proliferative diabetic retinopathy (NPDR). Materials and Methods: Ninety eyes of patients with mild-to-moderate NPDR that underwent phacoemulsification cataract surgery were divided into three groups. A detailed description of the clinical study protocol is described later in paper. In short, Group 1 received topical bromfenac (0.9 mg/mL), Group 2 dexamethasone (1 mg/mL), and Group 3 placebo, both preoperatively and postoperatively. Additionally, all patients received combined topical steroid and antibiotic drops (dexamethasone, neomycin and polymyxin B) 3 weeks postoperatively. On the day of the surgery, aqueous humour samples (0.1–0.2 mL) were obtained and IL-6 concentrations were analysed. Central foveal subfield thickness (CFT) measured using spectral-domain optical coherence tomography (SD-OCT) was analysed preoperatively and postoperatively. Results: There was no significant difference in IL-6 concentrations between groups. Postoperative CFT was significantly lower in the dexamethasone group compared to the placebo group. In addition, the correlation between IL-6 and CFT was statistically significant in the dexamethasone group. No patient developed PCME in any of the three groups. No adverse events were reported during the study. Conclusion: Topical bromfenac and dexamethasone have no significant effect on intraocular IL-6 concentration in patients with NPDR. Topical bromfenac is not more effective than topical dexamethasone in reducing postoperative CFT in patients with NPDR. |
format | Online Article Text |
id | pubmed-9694649 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96946492022-11-26 Pseudophakic Cystoid Macular Oedema (PCME) Prevention in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)—Randomized Controlled Trial Jukić, Anđela Kasalica Žužul, Rajka Pavan, Josip Lovrić, Mila Kozmar, Ana Plavec, Davor Kuzman, Tomislav Kalauz, Miro Jukić, Tomislav Medicina (Kaunas) Article Background and Objectives: The purpose of this study was to compare the effect of topical bromfenac and dexamethasone on the intraocular concentration of interleukin 6 (IL-6) and incidence of pseudophakic cystoid macular oedema (PCME) after cataract surgery in patients with non-proliferative diabetic retinopathy (NPDR). Materials and Methods: Ninety eyes of patients with mild-to-moderate NPDR that underwent phacoemulsification cataract surgery were divided into three groups. A detailed description of the clinical study protocol is described later in paper. In short, Group 1 received topical bromfenac (0.9 mg/mL), Group 2 dexamethasone (1 mg/mL), and Group 3 placebo, both preoperatively and postoperatively. Additionally, all patients received combined topical steroid and antibiotic drops (dexamethasone, neomycin and polymyxin B) 3 weeks postoperatively. On the day of the surgery, aqueous humour samples (0.1–0.2 mL) were obtained and IL-6 concentrations were analysed. Central foveal subfield thickness (CFT) measured using spectral-domain optical coherence tomography (SD-OCT) was analysed preoperatively and postoperatively. Results: There was no significant difference in IL-6 concentrations between groups. Postoperative CFT was significantly lower in the dexamethasone group compared to the placebo group. In addition, the correlation between IL-6 and CFT was statistically significant in the dexamethasone group. No patient developed PCME in any of the three groups. No adverse events were reported during the study. Conclusion: Topical bromfenac and dexamethasone have no significant effect on intraocular IL-6 concentration in patients with NPDR. Topical bromfenac is not more effective than topical dexamethasone in reducing postoperative CFT in patients with NPDR. MDPI 2022-11-17 /pmc/articles/PMC9694649/ /pubmed/36422204 http://dx.doi.org/10.3390/medicina58111667 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Jukić, Anđela Kasalica Žužul, Rajka Pavan, Josip Lovrić, Mila Kozmar, Ana Plavec, Davor Kuzman, Tomislav Kalauz, Miro Jukić, Tomislav Pseudophakic Cystoid Macular Oedema (PCME) Prevention in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)—Randomized Controlled Trial |
title | Pseudophakic Cystoid Macular Oedema (PCME) Prevention in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)—Randomized Controlled Trial |
title_full | Pseudophakic Cystoid Macular Oedema (PCME) Prevention in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)—Randomized Controlled Trial |
title_fullStr | Pseudophakic Cystoid Macular Oedema (PCME) Prevention in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)—Randomized Controlled Trial |
title_full_unstemmed | Pseudophakic Cystoid Macular Oedema (PCME) Prevention in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)—Randomized Controlled Trial |
title_short | Pseudophakic Cystoid Macular Oedema (PCME) Prevention in Patients with Non-Proliferative Diabetic Retinopathy (NPDR)—Randomized Controlled Trial |
title_sort | pseudophakic cystoid macular oedema (pcme) prevention in patients with non-proliferative diabetic retinopathy (npdr)—randomized controlled trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9694649/ https://www.ncbi.nlm.nih.gov/pubmed/36422204 http://dx.doi.org/10.3390/medicina58111667 |
work_keys_str_mv | AT jukicanđela pseudophakiccystoidmacularoedemapcmepreventioninpatientswithnonproliferativediabeticretinopathynpdrrandomizedcontrolledtrial AT kasalicazuzulrajka pseudophakiccystoidmacularoedemapcmepreventioninpatientswithnonproliferativediabeticretinopathynpdrrandomizedcontrolledtrial AT pavanjosip pseudophakiccystoidmacularoedemapcmepreventioninpatientswithnonproliferativediabeticretinopathynpdrrandomizedcontrolledtrial AT lovricmila pseudophakiccystoidmacularoedemapcmepreventioninpatientswithnonproliferativediabeticretinopathynpdrrandomizedcontrolledtrial AT kozmarana pseudophakiccystoidmacularoedemapcmepreventioninpatientswithnonproliferativediabeticretinopathynpdrrandomizedcontrolledtrial AT plavecdavor pseudophakiccystoidmacularoedemapcmepreventioninpatientswithnonproliferativediabeticretinopathynpdrrandomizedcontrolledtrial AT kuzmantomislav pseudophakiccystoidmacularoedemapcmepreventioninpatientswithnonproliferativediabeticretinopathynpdrrandomizedcontrolledtrial AT kalauzmiro pseudophakiccystoidmacularoedemapcmepreventioninpatientswithnonproliferativediabeticretinopathynpdrrandomizedcontrolledtrial AT jukictomislav pseudophakiccystoidmacularoedemapcmepreventioninpatientswithnonproliferativediabeticretinopathynpdrrandomizedcontrolledtrial |